CatalYm today announced final results from its randomized Phase 2 GDFATHER-NEO trial, which were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 and simultaneously published in Nature Medicine. The data showed that Growth Differentiation…
High Blood Glucose Levels Linked to Higher Risk of Wound Complications The researchers analyzed rates of wound-related complications in 79 patients undergoing surgery for closure of chronic wounds -- a common and troublesome complication of diabetes. Blood glucose levels were measured five…
The award supports manufacturing of vaccine doses for clinical evaluation and outbreak response, clinical and regulatory activities including a Phase 1 trial, and options for expanded manufacturing to support future preparedness needs, as well as development of an updated vaccine candidate…
A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease. Francesco Forconi: I am a Professor of Hematology at the University of Southampton, practicing at Southampton General Hospital. I…
Faustine Nouvel, of the Department of Medical Oncology at Gustave Roussy, presented the findings in a poster at the 2026 European Society for Medical Oncology (ESMO) Congress. Overall, the median OS from diagnosis in the FGFR-altered population was 38.4 months (95% CI, 32.4-55.3). From…
Data from the phase 3 OptiTROP-Lung06 trial may support sacituzumab tirumotecan plus pembrolizumab as a new frontline option for this NSCLC population. At a median follow-up of 9.7 months in this prespecified interim analysis, the median PFS by blinded independent central review…
Brass Knuckle Transformer (BKDST-1040NP) offers versatile protection for eyes against threats like debris and fog. These glasses quickly transition from standard temples to an elastic head strap. Integrated side protection remains and so does the exclusive BK-Anti-FOG+ protection. Brass Knuckle…
In STARBOARD, frontline encorafenib, binimetinib, and pembrolizumab improved ORR and PFS vs pembrolizumab alone in BRAF V600E/K-mutant melanoma. The confirmed ORR per blinded independent central review (BICR) was 70.0% (95% CI, 60.9%-77.8%) with the triplet vs 32.7% (95% CI, 24.7%-41.9%) with placebo plus pembrolizumab (odds ratio…
— Julia Riley highlights diagnostic delays and barriers to care Hidradenitis suppurativa (HS) disproportionately affects Black patients, who may experience more severe disease, longer diagnostic delays, and greater healthcare utilization, according to Julia M. Riley, MD, of Northwestern University Feinberg School…
A phase 2 trial evaluates the safety and efficacy of loncastuximab tesirine plus rituximab among older, unfit or frail patients with previously untreated diffuse large B-cell lymphoma. Loncastuximab Plus Rituximab Raises Safety Concerns Despite Responses in Frail Patients With Untreated DLBCL…
Results of clinical trials across diseases: phase 2 and phase 3 readouts, survival and efficacy data, and what they mean for patients.
An article joins this feed when it matches these terms. Each one is also a search of its own.